180 Life Sciences (NASDAQ:ATNF) (NASDAQ:ATNF) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates across two primary platforms: pain management and oncology. The company’s pain platform focuses on novel non-opioid small molecules designed to address both acute and chronic pain, including indications such as osteoporotic fracture pain and complex regional pain syndrome. Its oncology platform leverages peptide-based immunotherapy and targeted small molecules to tackle hormone-resistant and WT1-expressing solid tumors.
Within its pain management portfolio, 180 Life Sciences is advancing proprietary combination therapies through late preclinical and early clinical studies. These programs employ innovative formulation technology to enhance drug delivery, aiming for rapid onset of pain relief while minimizing dependency and opioid-related side effects. The company’s strategy includes broadening its pipeline to address neuropathic pain and other high-unmet medical needs, positioning its candidates as potential alternatives to traditional analgesics.
On the oncology front, the company has licensed immunotherapeutic technology targeting the Wilms’ tumor 1 (WT1) antigen, which is overexpressed in a variety of solid tumors. Early-stage clinical trials are assessing the safety, immunogenicity, and potential efficacy of these WT1-directed candidates, with the goal of eliciting robust T-cell responses against malignant cells. In parallel, 180 Life Sciences is exploring small-molecule inhibitors aimed at overcoming endocrine resistance in breast and ovarian cancers, blending targeted and immunotherapeutic approaches within its pipeline.
Formed through strategic mergers and asset acquisitions, 180 Life Sciences maintains research and development centers in Basel, Switzerland; Cambridge, Massachusetts; and Tel Aviv, Israel. Under the leadership of Chief Executive Officer Yaniv Harel and a management team of seasoned industry professionals, the company continues to expand its pipeline through internal discovery efforts and collaborative partnerships. Its global footprint and diversified platform approach position 180 Life Sciences to advance multiple clinical programs across North America, Europe, and other international markets.
